Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather than second line
endocrine treatment, the aim of this project is to evaluate whether the sequence of an
aromatase inhibitor plus CDK 4/6 in first line followed by fulvestrant in second line is
superior to the sequence of an aromatase inhibitor in first line followed by fulvestrant plus
CDK4/6 in second line.